PM
ALDX icon

Prosight Management’s Aldeyra Therapeutics ALDX Stock Holding History

Prosight Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-671,200
Closed -$10K – 42
2023
Q2 		$10K Buy
+671,200
New +$6.61M ﹤0.01% 37
2019
Q2 		– Sell
-162,300
Closed -$1.47M – 40
2019
Q1 		$1.47M Buy
+162,300
New +$1.38M 0.64% 33

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management's ALDX Position: Q3 2023 in Review

Prosight Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 149,511 shares — an estimated $1.25M sold.

Prosight Management first reported a position in ALDX in Q4 2018 and held it in 19 quarters. The position peaked at $8.3M in Q4 2019. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

  • Prosight Management reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Prosight Management sold 149,511 Aldeyra Therapeutics shares in Q3 2023, an estimated $1.25M.
  • Prosight Management first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 19 quarters.
  • Prosight Management's Aldeyra Therapeutics position peaked at $8.3M in Q4 2019.
  • 120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on Prosight Management's 13F filing for Q3 2023, filed 14 Nov 2023.